Efficacy and Safety of Relacorilant in Individuals With Adrenal Hypercortisolism: Results From the Phase 3 GRACE and GRADIENT Studies

Summary

• Relacorilant resulted in clinically and statistically significant treatment benefits in participants with adrenal hypercortisolism in the phase 3 GRACE and GRADIENT studies
• Compared with placebo, relacorilant treatment:
  • Significantly reduced systolic and diastolic blood pressure in participants with hypertension
  • Improved fasting glucose and glucose area under the curve in participants with hyperglycemia
  • Resulted in significant weight loss
• Across studies, relacorilant was well-tolerated in participants with adrenal hypercortisolism
• There were no cases of adrenal insufficiency or vaginal bleeding associated with endometrial hypertrophy, and no cases of drug-induced hypokalemia or QT interval prolongation

Download poster